Watson Pharmaceuticals reported Tuesday that U.S. regulators cleared the company’s oral contraceptive product Vestura, which is a generic version of Bayer’s Yaz (drospirenone/ethinyl estradiol).
Watson noted that it is currently involved in patent litigation with Bayer concerning the drug. However, Watson did not comment further on the legal matters or say how the approval impacts the suit.
Yaz had US sales of $173 million for the 12 months ended September 30, according to Watson. Teva last June launched a generic version of the oral contraceptive in the US.
